ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012 Financial Results

Tue Feb 5, 2013 7:35am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130205:nBw055257a

CAMBRIDGE, Mass.--(Business Wire)--
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a
live webcast of its quarterly conference call at 8:30 a.m. (ET) on Monday,
February 25, 2013. Harvey J. Berger, M.D., chairman and chief executive officer,
will host the call. Senior management will discuss the Company`s financial
results as of December 31, 2012, key corporate objectives and additional
corporate activities. The Company will announce the highlights of these topics
in a press release to be issued before the market opens on February 25, 2013
prior to the conference call. 

The live webcast can be accessed by visiting the investor relations section of
the Company`s website at http://investor.ariad.com. The call can be accessed by
dialing 866-831-6272 (domestic) or 617-213-8859 (international) five minutes
prior to the start time and providing the pass code 59632303. A replay of the
call will be available on the ARIAD website approximately two hours after
completion of the call and will be archived for three weeks. 

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform the lives
of cancer patients. ARIAD`s first medicine, Iclusig, is approved in the U.S. for
the treatment of adult patients with chronic, accelerated or blast phase chronic
myeloid leukemia that is resistant or intolerant to prior tyrosine kinase
inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic
leukemia that is resistant or intolerant to prior TKI therapy. Additional
clinical trials of Iclusig in other cancers are ongoing. ARIAD is also studying
AP26113, another molecularly targeted medicine, in certain forms of lung cancer.
For additional information, visit http://www.ariad.com or follow ARIAD on
Twitter (@ARIADPharm).

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-621-2208
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.